Dermatology Research and Practice

Clinical Study

Evaluation of the Quantitative and Qualitative Alterations in the Fatty Acid Contents of the Sebum of Patients with Inflammatory Acne during Treatment with Systemic Lymecycline and/or Oral Fatty Acid Supplementation

Table 2

Descriptive statistic of twelve fatty acids that presented changes during the study, based on group treatment and visits.
Fatty acidVisitGroup 1 ( )Group 2 ( )Group 3 ( )
Average (sd)Median (min.–max.)Average (sd)Median (min.–max.)Average (sd)Median (min.–max.)
C12:0D00.3 (0.4)0.0 (0–0.9)0.3 (0.4)0.0 (0–1.4)0.4 (0.5)0.0 (0–1.2)
D300.5 (0.4)0.7 (0–0.9)0.3 (0.4)0.0 (0–0.9)0.8 (0.3)0.8 (0–1.4)
D600.7 (0.4)0.8 (0–1.1)0.6 (0.7)0.3 (0–2.1)0.6 (0.5)0.7 (0–1.7)
D900.6 (0.5)0.7 (0–1.3)0.3 (0.4)0.0 (0–1.0)0.7 (0.4)0.8 (0–1.1)
C14:0D05.7 (2.2)6.1 (1.2–9.4)5.8 (1.8)5.7 (3.4–10.4)5.7 (1.7)6.1 (1.5–7.3)
D305.8 (1.0)5.4 (4.7–7.8)5.5 (0.7)5.3 (4.5–6.8)5.8 (1.2)5.8 (3.3–7.9)
D605.9 (1.4)6.0 (2.9–7.7)5.8 (1.4)5.9 (2.6–8.0)6.3 (1.4)6.1 (4.5–10.4)
D906.5 (1.0)6.1 (5.0–8.2)6.1 (1.3)6.3 (2.9–8.3)6.7 (1.3)6.9 (4.9–8.7)
C15:0D03.7 (1.3)4.3 (0.9–5.1)3.9 (1.1)4.0 (1.9–5.5)3.6 (1.0)3.7 (1.0–4.7)
D304.0 (0.6)3.8 (3.1–5.4)3.7 (0.6)3.7 (2.9–5.4)3.7 (0.7)3.7 (1.9–4.8)
D603.8 (0.9)3.8 (2.0–4.8)3.9 (0.7)4.1 (2.1–4.8)4.0 (0.9)4.1 (2.8–6.3)
D904.2 (0.6)4.1 (3.4–5.5)4.3 (0.7)4.3 (2.2–5.4)4.3 (0.7)4.4 (2.8–5.2)
C16:1D014.6 (5.3)17.2 (2.8–18.3)16.3 (4.4)17.2 (8.6–24.9)15.3 (4.5)16.1 (3.5–21.1)
D3016.2 (3.2)15.3 (12.5–21.4)15.2 (1.7)15.4 (12.4–17.9)16.3 (3.1)15.9 (8.9–20.9)
D6016.3 (4.2)17.7 (8.0–21.2)16.6 (3.9)17.7 (7.1–21.0)17.0 (2.5)16.9 (12.3–22.1)
D9018.8 (3.4)18.7 (13.2–25.1)19.2 (3.4)19.6 (12.2–25.1)18.8 (3.4)18.7 (13.2–25.1)
C18:0D03.7 (1.4)3.3 (1.8–6.6)3.8 (1.3)3.9 (2.3–6.5)3.6 (1.1)3.4 (2.5–6.0)
D302.8 (0.6)2.8 (1.9–4.2)3.7 (1.5)3.1 (2.1–8.0)3.0 (0.8)2.8 (2.2–5.2)
D602.7 (0.5)2.8 (1.9–3.5)3.4 (1.1)3.3 (1.9–5.3)3.3 (1.1)3.0 (2.2–5.4)
D902.6 (0.8)2.5 (1.9–5.0)3.3 (1.5)2.6 (1.7–6.4)3.3 (0.9)3.3 (2.0–5.4)
C18:1n9c+C18:1n9tD08.5 (2.9)8.8 (3.3–12.9)10.2 (2.3)10.7 (6.3–14.1)9.6 (2.1)9.8 (3.9–13.4)
D308.2 (2.0)8.0 (4.0–11.4)9.7 (2.5)9.2 (6.5–16.8)9.2 (1.4)9.0 (6.6–12.0)
D608.3 (1.7)8.0 (5.4–11.9)9.4 (2.5)9.6 (4.1–13.0)9.7 (1.7)9.7 (7.8–13.9)
D908.3 (1.6)7.9 (6.5–12.2)9.2 (1.9)8.9 (5.7–13.0)9.6 (1.5)9.5 (7.4–12.1)
C18:2n6tD00.2 (0.3)0.0 (0–0.8)0.6 (0.6)0.4 (0–1.8)0.3 (0.5)0.0 (0–1.3)
D300.5 (0.5)0.6 (0–1.3)0.5 (0.7)0.3 (0–2.4)0.6 (0.3)0.7 (0–1.1)
D600.4 (0.5)0.3 (0–1.1)0.5 (0.5)0.6 (0–1.4)0.7 (0.6)0.8 (0–2.3)
D900.3 (0.4)0.1 (0–1.2)0.4 (1.0)0.0 (0–3.6)0.4 (0.6)0.0 (0–1.9)
C18:3n6D00.3 (0.9)0.0 (0–3.3)0.2 (0.8)0.0 (0–3.0)0.1 (0.4)0.0 (0–1.7)
D300.6 (1.1)0.0 (0–3.7)0.3 (0.6)0.0 (0–1.8)0.7 (1.5)0.0 (0–5.5)
D600.8 (1.8)0.0 (0–6.2)1.7 (2.5)0.0 (0–8.2)0.7 (0.9)0.3 (0–2.3)
D900.0 (0.1)0.0 (0–0.5)0.3 (0.9)0.0 (0–3.1)0.3 (0.7)0.0 (0–2.1)
C18:3n3D00.3 (1.1)0.0 (0–3.9)0.5 (1.3)0.0 (0–4.5)1.0 (1.7)0.0 (0–4.4)
D300.2 (0.7)0.0 (0–2.6)0.2 (0.8)0.0 (0–3.1)0.3 (1.1)0.0 (0–3.9)
D600.0 (0.0) 0.0 (0-0)0.0 (0.0)0.0 (0-0)0.0 (0.0)0.0 (0-0)
D900.0 (0.0)0.0 (0-0)0.0 (0.0)0.0 (0-0)0.0 (0.1)0.0 (0–0.4)
C20:1D02.1 (5.6)0.0 (0–19.4)0.3 (1.1)0.0 (0–4.2)2.9 (5.9)0.4 (0–22.1)
D300.2 (0.7)0.0 (0–2.4)0.2 (0.8)0.0 (0–3.1)0.0 (0.0)0.0 (0-0)
D600.0 (0.1)0.0 (0–0.5)0.0 (0.0)0.0 (0-0)0.0 (0.0)0.0 (0-0)
D900.0 (0.0)0.0 (0-0)0.0 (0.0)0.0 (0-0)0.0 (0.0)0.0 (0-0)
C22:0D00.9 (1.9)0.0 (0–6.4)0.4 (1.2)0.0 (0–4.5)0.3 (1.3)0.0 (0–4.8)
D300.1 (0.3)0.0 (0–0.9)0.0 (0.0)0.0 (0-0)0.0 (0.2)0.0 (0–0.6)
D600.0 (0.0)0.0 (0-0)0.0 (0.0)0.0 (0-0)0.0 (0.1)0.0 (0–0.4)
D900.0 (0.0)0.0 (0-0)0.0 (0.0)0.0 (0-0)0.0 (0.0)0.0 (0-0)
C24:0D00.4 (0.5)0.0 (0–1.3)0.3 (0.4)0.0 (0–1.0)0.4 (0.6)0.0 (0–1.4)
D300.6 (0.5)0.7 (0–1.6)0.5 (0.4)0.7 (0–1.0)0.7 (0.6)0.7 (0–1.8)
D600.5 (0.6)0.0 (0–1.4)0.3 (0.4)0.0 (0–1.0)0.5 (0.6)0.6 (0–1.6)
D900.3 (0.4)0.0 (0–0.9)0.6 (0.5)0.9 (0–1.2)0.5 (0.5)0.3 (0–1.7)